The pharmaceutical company selected Leah's AI-powered CLM platform for its sophisticated approach to contract intelligence and operational flexibility. The decision came down to several key differentiators that aligned precisely with their pharmaceutical contracting requirements.
Leah's Leah capabilities offered automatic contract assessment against predefined playbooks, generating intelligent redlines that could reduce hours or weeks of manual review to minutes. Unlike simple clause replacement tools, the platform's surgical strike approach to redlining preserved context and nuance—critical for pharmaceutical negotiations where every legal term carries significant weight. The AI could be trained on acceptable primary, secondary, and tertiary fallback language positions, enabling the non-attorney contract associates to handle negotiations that previously required expensive legal escalations.
The platform's contract intelligence capabilities addressed a pain point the team had recently experienced firsthand. After manually reviewing 5,000 contracts to identify specific clauses, the ability to instantly query across their repository and understand where risk language existed represented transformational value. The one-drop functionality—allowing users to drag and drop contracts for automatic OCR, clause extraction, attribute identification, and both precedent-based and playbook-based redlining—directly addressed their workflow where documents already had established records before counterparty redlines arrived.
For a pharmaceutical organization processing complex regulatory agreements, the compliance monitoring and risk assessment capabilities provided systematic oversight that previous repository-only approaches couldn't deliver. The platform offered insight into master agreements, vendor risk concentration, and pathways to systematically de-risk relationships over time—essential capabilities for an organization managing extensive third-party vendor risks under rigorous regulatory requirements.
"In pharmaceutical drug discovery with extensive regulatory requirements and third-party vendor risks, the platform gives us insight into our master agreements, where risk lies, and how to systematically de-risk relationships over time."
— Senior Director of Business Operations
The operational dashboarding provided real-time visibility into contract volume, types, and team workload distribution—capabilities impossible with the previous system despite thousands of annual contracts flowing through an eight-person team. This transparency would enable data-driven resource allocation and proactive bottleneck identification for the first time.
The platform's no-code configuration approach and workflow flexibility proved critical during the evaluation and early implementation. The ability to configure conditional logic for privacy-related intake questions, create sophisticated auto-assignment rules, and customize workflows to support selective subject matter expert escalation demonstrated the platform could adapt to pharmaceutical-specific requirements without extensive custom development.
Perhaps most significantly, when implementation challenges emerged around product expectations and scope complexity, Leah demonstrated partnership commitment by pivoting strategy mid-implementation. The company added Leah standalone access for immediate training while building CLM workflows in parallel, expanded the contract rather than forcing the customer into an unsuitable product configuration, and refocused on proving value through a targeted NDA implementation before expanding to complex contract types.
With Leah's AI-powered contract analysis, operational visibility capabilities, and flexible implementation approach, the pharmaceutical organization positioned itself to transform contract operations from a manual bottleneck into a strategic operational advantage. The broader enterprise organization's interest in the implementation results signals confidence that the platform will deliver on its pharmaceutical contracting promise.
